Yi-Bin Chen, MD, reflects on the patient case and outlines strategies for educating and managing patients at risk of developing chronic GVHD.
Case: A 42-Year-Old Woman With Moderate Steroid-Refractory Chronic Graft-Versus-Host Disease
Initial Presentation
First-line Treatment
Second-line Treatment
Patient is now receiving ruxolitinib 10 mg orally twice daily, alongside 1 mg/kg/day steroids
Survival Benefits Shown After Stem Cell Transplant With Orca-T Vs PTCy
February 26th 2024Orca-T demonstrated survival rates vs post-transplant cyclophosphamide in patients with hematologic malignancies receiving myeloablative conditioning, according to findings from a retrospective analysis.
Read More
Improving Access to Bone Marrow Transplant and Cellular Therapies
February 19th 2024Stem cell treatments offer hope for a variety of conditions. However, access to these potentially life-altering procedures is often hampered by social factors such as socioeconomic status, race, cultural background, and geographic location.
Read More
Acyclovir Prophylaxis Reduces Oral Mucositis Incidence in HSCT Recipients
February 18th 2024Adding prophylactic acyclovir therapy to the treatment regimen for patients undergoing a stem cell transplant reduced the rates of chemotherapy-induced oral mucositis, a common and significant adverse effect of the treatment.
Read More